GLP-1 Medical Malpractice: Understanding Provider Liability
When GLP-1 prescribers fail to meet the standard of care, patients can suffer serious consequences. Here is what constitutes medical malpractice in the GLP-1 context and what options you have.
The rapid expansion of GLP-1 prescribing, particularly through telehealth, has created opportunities for excellent care and also for negligence. As millions of patients start semaglutide and tirzepatide, some encounter providers who prescribe without adequate evaluation, fail to monitor for complications, or ignore contraindications. Understanding what constitutes malpractice helps you evaluate the quality of care you receive.
Disclaimer
This article provides general legal information and is not legal advice. Medical malpractice law varies by state. Consult a qualified malpractice attorney for case-specific guidance.
The Four Elements of Medical Malpractice
To establish a medical malpractice claim, four elements must be proven. First, duty: the provider had a doctor-patient relationship with you. Second, breach: the provider's care fell below the accepted standard of practice. Third, causation: the breach directly caused your injury. Fourth, damages: you suffered measurable harm (medical costs, lost wages, pain and suffering).
Common GLP-1 Malpractice Scenarios
- Prescribing with contraindications: Giving GLP-1 medication to patients with personal or family history of medullary thyroid carcinoma, active pancreatitis, or known allergies
- Inadequate evaluation: Prescribing without reviewing medical history, current medications, or relevant lab work
- Failure to monitor: Not scheduling or conducting follow-up assessments, especially during dose escalation
- Incorrect dosing: Starting at too high a dose, escalating too quickly, or not adjusting for kidney or liver function
- Drug interaction negligence: Not reviewing for dangerous interactions with insulin, sulfonylureas, or other medications
- Informed consent failure: Not discussing known risks, alternatives, and expected outcomes before prescribing
The Telehealth Standard of Care
Telehealth GLP-1 prescribing is held to the same legal standard as in-person care. This means telehealth providers must conduct a thorough medical history review, evaluate contraindications and drug interactions, obtain informed consent, provide dose titration guidance, offer monitoring and follow-up, and be accessible for questions and concerns. The convenience of telehealth does not excuse shortcuts in clinical care.
What Good GLP-1 Care Looks Like
Standard of Care Benchmarks
- Comprehensive medical history review before prescribing
- Discussion of risks, benefits, and alternatives (informed consent)
- Appropriate starting dose with gradual titration
- Regular follow-up during dose escalation (every 4-6 weeks)
- Monitoring for GI side effects, gallbladder symptoms, and pancreatitis signs
- Instruction to discontinue and seek care if experiencing severe symptoms
- Accessible provider communication for questions between visits
How to Protect Yourself
Choose providers who conduct thorough evaluations before prescribing, not those who will prescribe to anyone who pays. Ask about the provider's credentials, their process for monitoring patients, and how to reach them if you have concerns. Providers who rush through evaluations, never follow up, or are unreachable between visits are providing substandard care regardless of how affordable their pricing is.
Keep copies of all communications with your provider, including messages, visit notes, and prescription records. If something goes wrong, these records become critical evidence. Also keep a symptom journal documenting any side effects, when they occurred, and what you reported to your provider.
What to Do If You Have Been Harmed
If you believe you received negligent GLP-1 care, take these steps immediately. Seek appropriate medical care for your current condition. Preserve all records and communications. Do not alter or delete any messages or documents. Consult a medical malpractice attorney, many offer free evaluations. File a complaint with your state medical board. And consider reporting to the FDA's MedWatch system if the medication itself was defective.
The Bottom Line
Medical malpractice in GLP-1 prescribing is preventable when providers follow established standards of care. As a patient, you deserve thorough evaluation, informed consent, appropriate monitoring, and accessible communication. Choose providers like Trimi that prioritize clinical quality alongside affordability, and do not hesitate to seek legal counsel if you believe you received negligent care.
Quality Medical Care from Trimi
Licensed providers, thorough evaluations, ongoing support. Semaglutide $99/mo, tirzepatide $125/mo.
View OptionsMore on legal & regulatory
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).